INTRODUCTION: Glucose transporter 1 (Glut-1) is a facilitative glucose transporter expressed in many cancers including breast cancer. Basal-like breast cancer (BLBC) is a high-risk disease associated with poor prognosis and lacks the benefit of targeted therapy. The aim of this study was to characterize the immunohistochemical (IHC) expression of Glut-1 in patients with BLBC compared with non-BLBC. MATERIALS AND METHODS: We identified 523 cases of invasive breast carcinoma from our database. The clinicopathologic findings and the biologic markers including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) status were reviewed. IHC stains for cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), p53, and Glut-1 were performed on tissue microarray using standard procedures. BLBC was defined as ER-,PR-, Her2-, and CK5/6+ and/or EGFR+. RESULTS: Of informative cases, 14.7% were categorized as BLBC versus 85.3% as non-BLBC. Glut-1 was expressed in 42 (76.4%) of 55 BLBCs, whereas only 55 (23.8%) of 231 non-BLBCs showed immunostaining for Glut-1 (P < .001). Overall, Glut-1 expression was significantly associated with high histologic grade, ER negativity, PR negativity, CK5/6 positivity, EGFR expression, and high p53 expression (P < .001). However, there was no correlation between Glut-1 immunostaining and patient's outcome. CONCLUSIONS: Our results show that Glut-1 is significantly associated with BLBC and might be a potential therapeutic target for this aggressive subgroup of breast cancer, and this warrants further investigations.
INTRODUCTION:Glucose transporter 1 (Glut-1) is a facilitative glucose transporter expressed in many cancers including breast cancer. Basal-like breast cancer (BLBC) is a high-risk disease associated with poor prognosis and lacks the benefit of targeted therapy. The aim of this study was to characterize the immunohistochemical (IHC) expression of Glut-1 in patients with BLBC compared with non-BLBC. MATERIALS AND METHODS: We identified 523 cases of invasive breast carcinoma from our database. The clinicopathologic findings and the biologic markers including estrogen receptor (ER), progesterone receptor (PR), and humanepidermal growth factor receptor 2 (Her2) status were reviewed. IHC stains for cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), p53, and Glut-1 were performed on tissue microarray using standard procedures. BLBC was defined as ER-,PR-, Her2-, and CK5/6+ and/or EGFR+. RESULTS: Of informative cases, 14.7% were categorized as BLBC versus 85.3% as non-BLBC. Glut-1 was expressed in 42 (76.4%) of 55 BLBCs, whereas only 55 (23.8%) of 231 non-BLBCs showed immunostaining for Glut-1 (P < .001). Overall, Glut-1 expression was significantly associated with high histologic grade, ER negativity, PR negativity, CK5/6 positivity, EGFR expression, and high p53 expression (P < .001). However, there was no correlation between Glut-1 immunostaining and patient's outcome. CONCLUSIONS: Our results show that Glut-1 is significantly associated with BLBC and might be a potential therapeutic target for this aggressive subgroup of breast cancer, and this warrants further investigations.
Authors: Dalia M Abd El-Rehim; Graham Ball; Sarah E Pinder; Emad Rakha; Claire Paish; John F R Robertson; Douglas Macmillan; Roger W Blamey; Ian O Ellis Journal: Int J Cancer Date: 2005-09-01 Impact factor: 7.396
Authors: Patrick L Fitzgibbons; Douglas A Murphy; M Elizabeth H Hammond; D Craig Allred; Paul N Valenstein Journal: Arch Pathol Lab Med Date: 2010-06 Impact factor: 5.534
Authors: R S Haber; A Rathan; K R Weiser; A Pritsker; S H Itzkowitz; C Bodian; G Slater; A Weiss; D E Burstein Journal: Cancer Date: 1998-07-01 Impact factor: 6.860
Authors: Alejandro Godoy; Viviana Ulloa; Federico Rodríguez; Karin Reinicke; Alejandro J Yañez; María de los Angeles García; Rodolfo A Medina; Mónica Carrasco; Sofía Barberis; Tamara Castro; Fernando Martínez; Ximena Koch; Juan Carlos Vera; María Teresa Poblete; Carlos D Figueroa; Bruno Peruzzo; Fernando Pérez; Francisco Nualart Journal: J Cell Physiol Date: 2006-06 Impact factor: 6.384
Authors: B K Linderholm; H Hellborg; U Johansson; G Elmberger; L Skoog; J Lehtiö; R Lewensohn Journal: Ann Oncol Date: 2009-06-23 Impact factor: 32.976
Authors: Sung Soo Kang; Yi Kyeong Chun; Min Hee Hur; Hae Kyung Lee; Yee Jeong Kim; Sung Ran Hong; Jee Hyun Lee; Sung Gong Lee; Yong Koo Park Journal: Jpn J Cancer Res Date: 2002-10
Authors: Shalini Jain; Xiao Wang; Chia-Chi Chang; Catherine Ibarra-Drendall; Hai Wang; Qingling Zhang; Samuel W Brady; Ping Li; Hong Zhao; Jessica Dobbs; Matt Kyrish; Tomasz S Tkaczyk; Adrian Ambrose; Christopher Sistrunk; Banu K Arun; Rebecca Richards-Kortum; Wei Jia; Victoria L Seewaldt; Dihua Yu Journal: Cancer Res Date: 2015-09-17 Impact factor: 12.701
Authors: Arthur Adams; Aram S A van Brussel; Jeroen F Vermeulen; Willem P Th M Mali; Elsken van der Wall; Paul J van Diest; Sjoerd G Elias Journal: BMC Cancer Date: 2013-11-10 Impact factor: 4.430
Authors: Jonathan M Ghergurovich; Jessica D Lang; Maren K Levin; Natalia Briones; Salvatore J Facista; Claudius Mueller; Alexis J Cowan; Matthew J McBride; Esther San Roman Rodriguez; Aaron Killian; Tuoc Dao; Jeffrey Lamont; Alison Barron; Xiaoyang Su; William P D Hendricks; Virginia Espina; Daniel D Von Hoff; Joyce O'Shaughnessy; Joshua D Rabinowitz Journal: Med (N Y) Date: 2021-04-14